SkinStim a Leonhardt Ventures LLC holding Announces Issuance of Pioneering Skin Regeneration U.S. Patent and Pilot Study Clinical Data
Irvine, California, United States - 07/13/2021 — SkinStim's unique combination bioelectric protein expression and biologics technology platform is designed to rejuvenate aging and damaged skin
Irvine, CA - July 13th, 2021 - SkinStim a Leonhardt Ventures LLC holding dedicated to developing innovative, clinically tested physician dispensed skin regeneration products, announced today that the United States Patent and Trademark office issued U.S. Patent 11,052,247 for Skin Treatment.
Link to Patent: https://patents.justia.com/patent/11052247 with 21 patent claims.
Abstract: A skin regeneration therapy combining precise bioelectric signals, light, and biologics for skin treatment and regeneration. Precise bioelectric signals give clear instructions to the stimulated cell DNA/RNA to produce specific regenerative proteins on demand. Bioelectric signals give clear instructions to cell membranes on what to let in and what to let out and serve as an equivalent or surrogate of environmental stimuli to cause a cell action in response.
The SkinStim team also announced today positive results from pilot clinical studies in South Africa and Utah. The stimulator used in these studies has FDA 510K clearance and CE mark for improving blood circulation and muscle tone. The company is carefully gathering data to submit to the FDA and other regulatory agencies to expand and broaden labelling indications of use.
"We are seeing positive results with the SkinStim combination bioelectric and biologics therapy that we have not seen with stand alone therapies previously tested." stated Dr. Catherine Davies, hair and skin restoration clinician, Author of Book PRF in Facial Aesthetics, Founder ZD Hair Clinic, Johannesburg, South Africa and host of Out Patients TV Show.
“We are incredibly proud of the scientific progress we have made in validating SkinStim performance in our combination bioelectric and biologics treatments in pilot clinical studies. Which is confirmed now further by numerous patents including this new one issued this week by the U.S.P.T.O. SkinStim is designed to combine the anti-aging benefits of improved blood circulation, improved muscle tone, bioelectric stem cell homing via SDF1 and PDGF, COL17A1 release for skin tightening, klotho release for potentially better UV light skin protection and tropoelastin release for improving elasticity. Our studies have demonstrated that by bioelectrically stimulating PRF (platelet rich fibrin) we can unlock, enhance and amplify skin regeneration promoting protein expressions such as PDGF. The secretome from amniotic sourcing used in our combination therapy we believe builds even further on the potential for positive skin regeneration results. We will now move this combination therapy into larger more statistically significant well controlled studies to further prove out both safety and efficacy working with leading skin care clinics worldwide." stated Howard J. Leonhardt, Co-Inventor and Executive Chairman and CEO of Leonhardt Ventures LLC and SkinStim.
SkinStim LTP is incubating in the Leonhardt's Launchpads incubator/accelerator labs in Utah and California.
Link to published Scientific and Related Supporting Articles on web site > https://skin-stim.com/related-articles/
About SkinStim: SkinStim LTP www.skin-stim.com founded in 2014 is focused on applying bioelectric signaling controlled regenerative protein expressions and when needed biologics injections or patches to skin regeneration. SkinStim via an exclusive license for skin use from Leonhardt Ventures LLC has over 100 patent claims issued or pending related to skin regeneration.
About Leonhardt Ventures LLC: Leonhardt Ventures LLC www.leonhardtventures.com founded in 1982 is the commercial arm of inventor Howard J. Leonhardt. In the 1980's the team patented, developed, manufactured and brought to market the PolyCath line of cardiovascular balloon catheters. In the 1990s the team patented and developed the first biological pacemaker, the first percutaneous heart valve StentValve and first practical endovascular stent graft for aortic aneurysm repair the TALENT (Taheri-Leonhardt) which today holds world leadership in non-surgical aortic aneurysm repair. In 2000's the team pioneered cell based repair of organs including the landmark first ever non-surgical muscle stem cell repair of a human heart in May of 2001. In 2005 they received the first patent combining bioelectrics and biologics for organ regeneration and repair. In 2019 they led a team that successfully completed the first implantations ever of a true aortic stent based circulatory assist pump placed without surgery via an endovascular catheter. Over 600,000 patients have been treated with Leonhardt inventions to date. Leonhardt published patents and patents pending may be found here - https://patents.justia.com/inventor/howard-j-leonhardt
About Leonhardt's Launchpads: Leonhardt's Launchpads is the innovation and startup launch accelerator arm of Leonhardt Ventures LLC founded in 2008 with R&D labs and research support offices in California, Utah, Minnesota, Pennsylvania, Australia, The Netherlands and Brazil. Leonhardt's Launchpads currently is helping accelerate 38 innovation assets in its 2021 portfolio https://leonhardtventures.com/development-pipeline/. Leonhardt's Launchpads receives 9% equity position in each organ or purpose specific innovation asset in exchange for their accelerator support and has pre-emptive right to purchase up to 20% equity ownership in each organ specific invention or startup right up to exit or graduation from the accelerator.
Disclaimer: Any patents mentioned may not be maintained. Any patents pending may not be issued. Products under development may not make it to market. All technologies mentioned are in early stages of development not yet proven to be either safe or effective in statistically significant controlled clinical trials. Early pilot study data may not be confirmed in large scale studies. Any forward looking statements are subject to change without notice.
Contact: Leonhardt Ventures LLC, 613 Iris Avenue, Corona Del Mar, CA 92625, Leonhardt;'s Launchpads, 5270 California Avenue, Irvine, CA 92617 email howard@leonhardtventures.com
Media Contacts:
Company Name: SkinStim by Leonhardt VenturesFull Name: Howard J. Leonhardt
Phone: (424) 291-2133
Email Address: Send Email
Website: www.leonhardtventures.com